Obeticholic acid is a farnesoid X receptor (FXR) agonist, is indicated for the treatment of primary biliary c h o l a n g i t i s (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.
Obeticholic acid is a semi-synthetic bile acid derivative used primarily for treating cholestatic liver diseases. Its core synthesis involves the functionalization of chenodeoxycholic acid. The compound features the molecular formula C24H36O5 and carries CAS No. 187980-23-2.
Contraindicated in patients with complete biliary obstruction. Strict storage required at controlled room temperature away from moisture. Clinical use demands monitoring for pruritus and hepatic decompensation risks.